Oanh Dang
Plus aucun poste en cours
Profil
Oanh Dang worked as a Director of Business Development at Sequenom, Inc. and Sirius Genomics, Inc. She was also a Principal at Novozymes A and a Manager of Business Development at Zymeworks BC, Inc. In 2014-2015, she served as the Vice President of Business Development at Cardiff Oncology, Inc. Dr. Dang received her undergraduate degree from the University of California, Davis and her doctorate from the University of California San Diego.
Anciens postes connus de Oanh Dang
| Sociétés | Poste | Fin |
|---|---|---|
| CARDIFF ONCOLOGY, INC. | Corporate Officer/Principal | 01/06/2015 |
Sirius Genomics, Inc.
 Sirius Genomics, Inc. Pharmaceuticals: MajorHealth Technology Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
| SEQUENOM, INC. | Corporate Officer/Principal | - |
Novozymes A/S
 Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Formation de Oanh Dang
| University of California, Davis | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARDIFF ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
Sequenom, Inc.
 Sequenom, Inc. Medical SpecialtiesHealth Technology Sequenom, Inc. engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in October 09, 1996 and is headquartered in Burlington, NC. | Health Technology |
Sirius Genomics, Inc.
Sirius Genomics, Inc. Pharmaceuticals: MajorHealth Technology Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada. | Health Technology |